Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Change in Receivables (2016 - 2025)

Perspective Therapeutics' Change in Receivables history spans 16 years, with the latest figure at -$46000.0 for Q3 2025.

  • For Q3 2025, Change in Receivables fell 131.29% year-over-year to -$46000.0; the TTM value through Sep 2025 reached -$154000.0, up 88.98%, while the annual FY2024 figure was -$1.0 million, 429.8% down from the prior year.
  • Change in Receivables for Q3 2025 was -$46000.0 at Perspective Therapeutics, down from $147000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $618000.0 in Q3 2023 and bottomed at -$813000.0 in Q2 2024.
  • The 5-year median for Change in Receivables is -$39000.0 (2022), against an average of -$59894.7.
  • The largest annual shift saw Change in Receivables surged 440.0% in 2021 before it plummeted 16700.0% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $68000.0 in 2021, then plummeted by 460.29% to -$245000.0 in 2022, then plummeted by 131.02% to -$566000.0 in 2023, then skyrocketed by 61.66% to -$217000.0 in 2024, then surged by 78.8% to -$46000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Change in Receivables are -$46000.0 (Q3 2025), $147000.0 (Q2 2025), and -$38000.0 (Q1 2025).